Skip to content
Vivo logo
← All articles

Peptide Therapy Safety: Risks, Side Effects and Screening

Peptide Therapy Safety: Risks, Side Effects and Screening

Isometric forms suggest peptide safety screening

Peptide therapy is not a single product with a single safety profile. Safety depends on which peptide is used, whether it is an FDA-approved medication, a compounded prescription or a research chemical, who prescribes it, and which pharmacy prepares it. FDA-approved peptide medications have large clinical trials behind them. For unregulated peptides, Harvard Health reports that the evidence is insufficient to determine safety.

This guide explains where the risks sit, which side effects are documented, what remains unknown, and how an adult considering telehealth can check a provider and pharmacy before starting.

VivoChoose Peptide Care With Medical OversightVivo offers provider-supervised treatments prepared by licensed U.S. pharmacies, with personalized treatment selection and HIPAA-compliant data practices.Explore Vivo care

TL;DR

  • “Peptide” covers very different products. Approved medications have safety data from large trials; research-grade and unregulated peptides do not.
  • Documented side effects include gastrointestinal symptoms, headache, fatigue and injection-site irritation. Long-term effects of many newer peptides are unknown.
  • Compounded drugs are not FDA-approved and have not had FDA premarket review, so provider and pharmacy screening matters.
  • A safe telehealth source requires screening and a prescription, uses a state-licensed pharmacy, and keeps a licensed clinician available for questions.
  • Health data handled by a telehealth provider falls under HIPAA, which allows certain uses for treatment, payment and operations.

Table of Contents

Why peptide safety is not one question

Peptides are short chains of amino acids. Some are long-established medicines, such as insulin and the GLP-1 drugs approved for diabetes and weight management. Others are sold online with claims about recovery, longevity or body composition, with little human research behind them.

The American Medical Association makes this distinction: insulin and FDA-approved GLP-1 medications have established, disease-specific uses, while newer peptides lack the same evidence base. That makes it hard for clinicians to advise patients on dosing and long-term risk.

Three categories tend to be blended in search results, and they carry different levels of risk.

Category Regulatory status What is known about safety Main concern
FDA-approved peptide medications Reviewed by FDA for safety, effectiveness and quality Studied in large clinical trials Known side effects, appropriate prescribing
Compounded prescription products Not FDA-approved; no FDA premarket review Depends on the drug, the pharmacy and the prescriber Quality, dosing errors, use only when an approved drug cannot meet the patient’s needs
Research-grade (“research use only”) peptides Not approved for human use; not reviewed for safety, efficacy or manufacturing Largely unstudied in humans Contamination, unknown effects, no clinical oversight

The FDA states that compounded drugs are not FDA-approved, meaning they have not undergone premarket review for safety, effectiveness or quality, and that they should only be used when a patient’s medical needs cannot be met by an approved drug. State medical boards have also issued a joint statement warning against administering or using research-grade peptides in people, because these products have not been reviewed for safety, efficacy or manufacturing standards.

Side effects and known risks

Common side effects

Harvard Health lists the reported side effects of peptides as gastrointestinal issues, headache, fatigue and injection-site irritation. Which of these occurs depends on the specific peptide and route, so the label and the prescriber’s instructions for the exact product are the reference, not a general list.

Four commonly reported peptide side effects

Irritation at the injection site is a reason to ask a prescriber about technique, rotation of sites and storage. Persistent gastrointestinal symptoms, or any symptom that worsens, belongs in a message to the prescribing clinician rather than a dose change made alone.

Immune reactions and pancreatic inflammation

The same Harvard Health review notes that some injectable peptides may trigger abnormal immune responses or allergic reactions, including severe ones, and may increase the risk of pancreatic inflammation. Immunogenicity, the tendency of a therapeutic peptide to provoke an immune response, is also a central topic in the pharmaceutical literature on peptide manufacturing and approval.

Signs that need urgent care include swelling of the face or throat, difficulty breathing, hives that spread, or severe persistent abdominal pain. Anyone with a history of pancreatitis should raise it with a licensed prescriber before any GLP-1 or related peptide is considered.

Contamination in unregulated products

Health Canada warns that unauthorized peptides may contain contaminants such as heavy metals, bacteria, endotoxins, or particles like glass or plastic. The warning comes from a Canadian regulator, but the underlying problem, products made without pharmaceutical quality controls, applies wherever such products are sold. For injectables, contamination is more serious because the product bypasses digestion.

What remains uncertain

Long-term effects of many peptides are unknown. Animal studies on research-grade peptides have suggested potential risks including organ damage, neurotoxicity and plaque formation, according to Stanford Medicine, though these effects remain largely unstudied in humans.

The Association of American Medical Colleges reports that some researchers are concerned about long-term risks of peptides such as BPC-157, KPV and GHK-Cu, because they stimulate angiogenesis, which could theoretically support the growth of existing tumors. The AAMC adds that significant research is needed on newer peptides before definitive recommendations can be made.

Stanford’s Svensson also cautions that using a compounding pharmacy may avoid some contamination risks but does not establish how a specific peptide affects human health over time. A clean product and a proven product are different things.

What remains uncertain

Adverse event reports for compounded GLP-1 drugs

The FDA reported that as of May 31, 2026, it had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. These are voluntary reports and do not establish how often events occur, but they show why dosing instructions, syringe or unit conversions and prescriber follow-up matter. A related comparison of the two drugs and the regulatory context is available in this semaglutide versus tirzepatide comparison. Our own overview of dosing-error concerns is in telehealth peptide therapy and GLP-1 dose errors.

What a licensed prescriber should assess

A safe prescribing process starts before any product ships. In practice, an adult should expect the following from a licensed telehealth provider:

  • A health history and screening. Current conditions, medications, allergies, prior reactions and relevant lab or wearable data are reviewed before approval. The FDA lists a failure to require screening and a prescription as a warning sign of an unsafe online source.
  • A treatment choice matched to the indication. The AMA’s concern is that newer peptides lack evidence for dosing and long-term risk, so a careful prescriber explains why a particular therapy fits and what evidence exists for it.
  • Clear dosing and administration instructions. This includes the route (nasal, injection or topical), the schedule, storage and what to do after a missed dose.
  • A defined follow-up. Ongoing oversight, a way to report side effects, and a plan for adjusting or stopping treatment.
  • Informed consent. Telehealth providers must follow federal and state rules that include state licensure and documented patient consent, according to HHS. Our guide to telehealth informed consent, state rules and HIPAA explains what a consent document should cover.

Who is allowed to prescribe also depends on the state where the patient lives. Our article on who prescribes peptides in the U.S. covers how location sets the rules.

How to check a telehealth provider and pharmacy

The FDA’s guidance on buying medicines online gives a practical checklist. Each item below rests on that FDA guidance.

  1. Confirm a prescription and screening are required. A provider that sells without either is a warning sign.
  2. Use a state-licensed pharmacy. Ask the provider which pharmacy prepares the medication and verify its license with the state board of pharmacy.
  3. Confirm a licensed doctor is available for questions. If follow-up questions cannot reach a licensed clinician, treat it as a red flag.
  4. Be wary of deep discounts and misleading claims. Very low prices and promises of guaranteed results are listed by the FDA as signs of an unsafe source.
  5. Use BeSafeRx. The FDA’s BeSafeRx campaign helps consumers learn how to buy medicines online safely.

Enforcement is active. The FDA’s annual compliance report states that it used online surveillance among other methods and issued 58 warning letters to telehealth companies selling misbranded compounded products in 2025. The same pressure applies to supply chains: in an updated import alert, the FDA said foreign-sourced GLP-1 active ingredients should be considered for detention without physical examination because 21% of 48 evaluated sites were noncompliant with current good manufacturing practice requirements. Asking where a pharmacy sources its ingredients is a reasonable question.

Privacy and health data in telehealth

Peptide therapy through telehealth involves sensitive information: medical history, prescriptions, sometimes lab results. Direct-to-consumer telehealth providers must comply with HIPAA, and HHS guidance notes their technology should integrate with existing electronic health record systems.

HIPAA is not a blanket promise that data is never shared. Under the HHS rules on treatment, payment and health care operations, providers may use or disclose protected health information for those purposes without patient authorization, and they must use reasonable safeguards when sharing it for treatment. Before enrolling, read the privacy notice and ask what is shared with the compounding pharmacy and for what purpose.

Our perspective

Vivo’s position is that peptide safety is mostly a question of process: who reviews the patient, who compounds the medication, and who is reachable afterward. We offer therapies including NAD+, glutathione, sermorelin, MIC+B12, semaglutide and tirzepatide only through a provider-supervised intake, with preparation by licensed U.S. pharmacies and delivery to the patient’s home.

Adults who have been tempted by research-chemical peptides are often looking for convenience and lower cost, not for risk. A licensed, supervised route removes the unknowns that regulators and academic medical centers warn about most: unverified sourcing, no screening, and no clinician to call.

We design our process around personalized treatment selection, medical supervision and HIPAA-compliant data practices. Compounded products are not FDA-approved, and we say so plainly. Our view is that a transparent, supervised pathway is the responsible way to use them.

Jack

Starting with a supervised plan

For adults who want a provider-reviewed option rather than an unsupervised source, Vivo offers prescription therapies after online intake and clinician approval. Published monthly prices are $129 for NAD+ nasal spray, $149 for glutathione nasal spray, $139 for sermorelin, $119 for MIC+B12 and $199 for tirzepatide and semaglutide. Approval depends on a provider’s review, and not every applicant is prescribed every therapy.

Frequently asked questions

Are peptides safe?

It depends on the product. FDA-approved peptide medications have been studied in large trials, while evidence for unregulated peptides is insufficient to determine safety, per Harvard Health. Risk falls when a licensed prescriber screens the patient and a state-licensed pharmacy prepares the product.

What are the most common peptide side effects?

Reported effects include gastrointestinal symptoms, headache, fatigue and injection-site irritation. Some injectable peptides may cause allergic or immune reactions, and long-term effects are unknown for many of them. Report any new symptom to the prescribing clinician.

Is a compounded peptide the same as an FDA-approved one?

No. Compounded drugs have not had FDA premarket review for safety, effectiveness or quality. The FDA says they should be used only when an approved drug cannot meet a patient’s medical needs, so the prescriber’s reasoning matters.

How can I tell whether a telehealth peptide provider is legitimate?

Look for required screening and a prescription, a state-licensed pharmacy, and a licensed doctor available for follow-up questions. Avoid deep discounts and misleading claims, and consult the FDA’s BeSafeRx resources before ordering online.

Are research-grade peptides a cheaper alternative?

They are not approved for human use and have not been reviewed for safety, efficacy or manufacturing standards. State medical boards warn against using them, and the lack of oversight is the central risk.

Sources